参考文献
- Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signaling controls tumor cell
growth. Nature, 2006, 441(7092): 424-430.[LinkOut]
- Pisick E, Jagadeesh S, Salgia R. Receptor tyrosine kinases and inhibitors in
lung cancer. Sci World J, 2004, 4: 589-604.[LinkOut]
- Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the
PIK3CA gene in human cancers. Science, 2004, 304(5670): 554.[LinkOut]
- Hartmann W, Digon-Sontgerath B, Koch A, et al. Phosphatidrl inositol 3'-kinase/
AKT signaling is actived in medulloblastoma cell proliferation and is
associated with reduced expression of PTEN. Cli Cancer Res, 2006, 12(10):
3019-3027.[LinkOut]
- Engelmann JA. Targeting PI3K signaling in cancer: opportunities, challenges
and limitations. Nat Rev Cancer, 2009, 9(8): 550-562.[LinkOut]
- Franke TF. PI3K/Akt: getting it right matters. Oncogene, 2008, 27(50):
6473-6488.[LinkOut]
- Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a
theme. Oncogene, 2008, 27(41): 5497-5510.[LinkOut]
- Sheng SJ, Qiao M, Pardee AB. Metastasis and AKT activation. J Cell Physiol,
2009, 218(3): 451-454.[LinkOut]
- Carnero A, Blanco-Aparicio C, Renner O, et al. The PTEN/PI3K/AKT
signaling pathway in cancer, therapeutic implications. Curr Cancer Drug
Targets, 2008, 8(3): 187-198.[LinkOut]
- Tokunaga E, Oki E, Egashira A, et al. Deregulation of the Akt pathway in human
cancer. Curr Cancer Drug Targets, 2008, 8(1): 27-36.[LinkOut]
- Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream.
Cell, 2007, 129(7): 1261-1274.[LinkOut]
- Rosivatz E. Inhibiting PTEN. Biochem Soc Trans, 2007, 35(Pt2): 257-259.[LinkOut]
- Downes CP, Perera N, Ross S, et al. Substrate specificity and acute regulation
of the tumor suppressor phosphatase, PTEN. Biochem Soc Symp, 2007, (74):
69-80.[LinkOut]
- Gao T. PHLPP: a phosphatase that directly dephosphorylates akt, promotes
apoptosis, and suppresses tumor growth. Mol Cell, 2005, 18(1): 13-24.[LinkOut]
- Duronio V. The life of a cell: apoptosis regulation by the PI3K/PKB pathway.
Biochem J, 2008, 415(3): 333-344.[LinkOut]
- Zhao L, Vogt PK. Class IPI3K in oncogenic cellular transformation. Oncogene,
2008, 27(41): 5486-5496.[LinkOut]
- Ali K, Bilancio A, Thomas M, et al. Essential role for the p110 delta phosphoinositide
3-kinase in the allergic response. Nature, 2004, 431(7011):
1007-1011.[LinkOut]
- Deb TB, Coticchia CM, Dickson RB. Calmodulin-mediated activation of
Akt regulates survival of c-Myc-overexpressing mouse mammary carcinoma
cells. J Biol Chem, 2004, 279(37): 38903-38911.[LinkOut]
- Qi HW, Fan LH. PI3K/Akt/mTOR signaling pathway and non-small cell
lung cancer. Chin J Lung Cancer, 2010, 13(12): 1149-1154. [祁慧薇, 范理
宏. PI3K/Akt/mTOR信号转导通路与非小细胞肺癌. 中国肺癌杂志,
2010, 13(12): 1149-1154.][LinkOut]
- Grille SJ, Bellacosa A, Upson J, et al. The protein kinase Akt induces epithelial
mesenchymal transition and promotes enhanced motility and invasiveness
of squamous cell carcinoma lines. Cancer Res, 2003, 63(9): 2172-2178.[LinkOut]
- Yan W, Fu Y, Tian D, et al. PI3 kinase/Akt signaling mediates epithelialmesenchymal
transition in hypoxic hepatocellular carcinoma cell. Bio Chem
Biophys Res Commun, 2009, 382(3): 631-636.[LinkOut]
- Steelman LS, Stadelman KM, Chappell WH, et al. Akt as a therapeutic target
in cancer. Expert Opin Ther Targets, 2008, 12(9): 1139-1165.[LinkOut]
- Kerbel RS. Tumor angiogenesis. N Engl J Med, 2008, 358(19): 2039-2049.[LinkOut]
- Katso R, Okkenhaug K, Ahmadi K, et al. Cellular function of phosphoinositide
3-kinases: implications for development, homeostasis, and cancer. Annu
Rev Cell Dev Biol, 2001, 17: 615-675.[LinkOut]
- Namiecinska M, Marciniak K, Nowak JZ. VEGF as an angiogenic, neurotrophic,
and neuroprotective factor. Postepy Hig Med Dosw, 2005, 59:
573-583.[LinkOut]
- Zhang R, Xu Y, Ekman N, et al. Etk/Bmx transactivates vascular endothelial
growth factor 2 and recruits phosphatidylinositol 3-kinase to mediate the
tumor necrosis factor-induced angiogenic pathway. J Biol Chem, 2003,
278(51): 51267-51276.[LinkOut]
- Kanaki T, Bujo H, Mori S, et al. Functional analysis of aortic endothelial cells
expressing mutant PDGF receptors with respect to expression of matrix metalloproteinase-
3. Biochem Biophys Res Commun, 2002, 294(2): 231-237.[LinkOut]
- Gately S, Kerbel R. Therapeutic potential of selective cyclooxygenase-2
inhibitors in the management of tumor angiogenesis. Prog Exp Tumor Res,
2003, 37: 179-192.[LinkOut]
- Thiel A, Heinonen M, Rintahaka J, et al. Expression of cyclooxygenase-2 is
regulated by GSK-3beta in gastric cancer cells. J Biol Chem, 2006, 281(8):
4564-4569.[LinkOut]
- Qian Y, Corum L, Meng Q, et al. PI3K induced actin filament remodeling
through Akt and p70S6K1: implication of essential role in cell migration. Am
J Physiol Cell Physio, 2004, 286(1): C153-C163.[LinkOut]
- Yin L, Liu JW, Guo YC, et al. Non-small cell lung cancer treatment status. J
Mod Oncol, 2010, 8(1): 185-187. [殷柳, 刘基巍, 郭英昌, 等. 非小细胞
肺癌治疗现状. 现代肿瘤医学, 2010, 8(1): 185-187.]
- Wangpaichitr M, Wu C, You M, et al. Inhibition of mTOR restores cisplatin
sensitivity through down-regulation of growth and anti-apoptotic proteins.
Eur J Pharmacol, 2008, 591(1-3): 124-127.[LinkOut]
- Fulda S. Targeting inhibitor of apoptosis proteins (IAPs) for cancer therapy.
Anticancer Agents Med Chem, 2008, 8(5): 533-539.[LinkOut]
- Brozovic A, Osmak M. Activation of mitogen-activated protein kinases by
cisplatin and their role in cisplatin-resistance. Cancer Lett, 2007, 251(1):
1-16.[LinkOut]
- Corradetti MN, Guan KL. Upstream of the mammalian target of rapamycin:
do all roads pass through mTOR? Oncogene, 2006, 25(48): 6347-6360.[LinkOut]
- Liu LZ, Zhou XD, Qian G, et al. AKT1 amplification regulates cisplatin resistance
in human lung cancer cells through the mammalian target of rapamycin/
p70S6K1 pathway. Cancer Res, 2007, 67(13): 6325-6332.[LinkOut]
- Yoeli-Lerner M, Toker A. Akt/PKB signaling in cancer: a function in cell
motility and invasion. Cell Cycle, 2006, 5(6): 603-605.[LinkOut]
- Henshall DC, Araki T, Schindler CK, et al. Activation of bcl-2 associated
death protein and counter-response of Akt within cell populations during
seizure-induced neuronal death. J Neurosci, 2002, 22(19): 8458-8465.[LinkOut]
- Coffey JC, Wang JH, Smith MJ, et al. Phosphoinositide 3-kinase accelerates
postoperative tumor growth by inhibiting apoptosis and enhancing resistance
to chemotherapy-induced apoptosis novel role for an old enemy. J Biol
Chem, 2005, 280(22): 20968-20977.[LinkOut]
- Alexia C, Bras M, Fallot G, et al. Pleiotropic effects of PI-3′kinase/Akt signaling
in human hepatoma cell proliferation and drug-induced apoptosis. Ann
N Y Acad Sci, 2006, 1090: 1-17.[LinkOut]
- Poh TW, Pervaiz S. LY294002 and LY303511 sensitize tumor cells to druginduced
apoptosis via intracellular hydrogen peroxide production independent
of the phosphoinositide 3-kinase-Akt pathway. Cancer Res, 2005,
65(14): 6264-6274.[LinkOut]
- Ihle NT, Wiliams R, Chow S, et al. Molecular pharmacology and antitumor
activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling.
Mol Cancer Ther, 2004, 3(7): 763-772.[LinkOut]
- Yu K, Lucas J, Zhu T, et al. PWT-458, a novel pegylated-17-hydroxywortmannin,
inhibits phosphatidylinositol 3-kinase signaling and suppresses
growth of solid tumors. Cancer Biol Ther, 2005, 4(5): 538-545.[LinkOut]
- Kim W, Seong J, An JH, et al. Enhancement of tumor radioresponse by wortmannin
in C3H/HeJ hepatocarcinoma. J Radiat Res (Tokyo), 2007, 48(3):
187-195.[LinkOut]
- Wu QG, Jiang GJ, Wang J. PI3K/Akt inhibitors on lung adenocarcinoma
A549 cells proliferation activity effect. Chin J Gerontol, 2011, 2(31): 278-280. [吴秋歌, 蒋军广, 王静. PI3K/Akt抑制剂对肺腺癌A549细胞
增殖活性的影响. 中国老年学杂志, 2011, 2(31): 278-280.]
- Sourbier C, Lindner V, Lang H, et al. The phosphoinositide 3-kinase/Akt
pathway: a new target in human renal cell carcinoma therapy. Cancer Res,
2006, 66(10): 5130-5142.[LinkOut]
- Kunnimalaiyaan M, Ndiaye M, Chen H, et al. Apoptosis-mediated medullary
thyroid cancer growth suppression by the PI3K inhibitor LY294002. Surgery,
2006, 140(6): 1009-1014.[LinkOut]
- Takeda A, Osaki M, Adachi K, et al. Role of the phosphatidylinositol
3-kinase-Akt signal pathway in the proliferation of human pancreatic ductal
carcinoma cell lines. Pancreas, 2004, 28(3): 353-358.[LinkOut]
- Huang Q. Advance in the relationship between PI3K/Akt and blood maliganancy.
Med Recap, 2010, 16(14): 2135-2137. [黄青. PI3K/Akt与血液恶性肿瘤关系的研究进展. 医学综述, 2010, 16(14): 2135-2137.]
- Zhang C, Yang N, Zhang WX, et al. Advances in kinase inhibitors targeting
PI3K-Akt-mTOR signal transduction pathway. Chin Oncol, 2006, 16(12):
1064-1070. [张超, 杨娜, 章雄文, 等. 靶向PI3K-Akt-mTOR信号通路抑
制剂的研究进展. 中国癌症杂志, 2006, 16(12): 1064-1070.]
- Nguyen DM, Chen GA, Reddy R, et al. Potentiation of paclitaxel eytotoxicity
in lung and esophageal cancer cells by pharmacologic inhibition of the
phosphinsitide 3-kinase/protein kinase B (Akt)-mediated signaling pathway.
J Thorac Cardiovasc Surg, 2004, 127(2): 365-375.[LinkOut]
|